Amoy Diagnostics Co., Ltd. Stock

Equities

300685

CNE1000034D3

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
21.1 CNY -1.31% Intraday chart for Amoy Diagnostics Co., Ltd. -3.12% -4.00%
Sales 2024 * 1.28B 177M Sales 2025 * 1.57B 216M Capitalization 8.33B 1.15B
Net income 2024 * 317M 43.79M Net income 2025 * 384M 53.05M EV / Sales 2024 * 5.95 x
Net cash position 2024 * 722M 99.79M Net cash position 2025 * 1.09B 151M EV / Sales 2025 * 4.62 x
P/E ratio 2024 *
26.5 x
P/E ratio 2025 *
21.9 x
Employees 1,119
Yield 2024 *
0.84%
Yield 2025 *
1.01%
Free-Float 64.5%
More Fundamentals * Assessed data
Dynamic Chart
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Amoy Diagnostics Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024. CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component A Share Index CI
Amoy Diagnostics Co., Ltd.(SZSE:300685) dropped from Shenzhen Stock Exchange Component Index CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Amoy Diagnostics to Collaborate with AstraZeneca Unit for Ovarian Cancer Companion Diagnostic in China MT
Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023 CI
Amoy Diagnostics Co., Ltd. Approves Final Dividend for 2022 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2022 CI
Amoy Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. and Precision Medicine Asia Co., Ltd. Announces the Japanese Ministry of Health, Labour and Welfare Approval in Japan as a Companion Diagnostic for Ret Fusion-Positive NSCLC CI
Tranche Update on Amoy Diagnostics Co., Ltd.'s Equity Buyback Plan announced on February 14, 2022. CI
More news
1 day-1.31%
1 week+0.43%
Current month-3.52%
1 month-7.01%
3 months+16.00%
6 months+3.89%
Current year-4.00%
More quotes
1 week
20.67
Extreme 20.67
22.27
1 month
20.10
Extreme 20.1
22.89
Current year
14.60
Extreme 14.6
24.03
1 year
14.60
Extreme 14.6
28.46
3 years
14.60
Extreme 14.6
61.39
5 years
14.60
Extreme 14.6
61.39
10 years
3.42
Extreme 3.4218
61.39
More quotes
Managers TitleAgeSince
Chief Executive Officer 41 11-12-31
Founder 71 08-02-20
Director of Finance/CFO 54 15-03-31
Members of the board TitleAgeSince
Founder 71 08-02-20
Chief Executive Officer 41 11-12-31
Director/Board Member 46 09-07-31
More insiders
Date Price Change Volume
24-04-25 21.1 -1.31% 4,431,898
24-04-24 21.38 +0.52% 4,408,660
24-04-23 21.27 -3.36% 7,214,446
24-04-22 22.01 +4.31% 5,585,833
24-04-19 21.1 -3.12% 5,904,875

End-of-day quote Shenzhen S.E., April 24, 2024

More quotes
Amoy Diagnostics Co Ltd is a pharmaceutical company engaged in research, development, production and sales of molecular diagnostic products. The Company provides testing reagents and testing services for tumor diagnosis. The Company’s testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The Company also provides data software to capture and analyze gene sequencing data. The Company provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
21.1 CNY
Average target price
29.55 CNY
Spread / Average Target
+40.04%
Consensus
  1. Stock Market
  2. Equities
  3. 300685 Stock